Skip to main content

Barclays Remains a Buy on Elevance Health (ELV)

Tipranks - Tipranks - Fri Jan 30, 2:41AM CST

In a report released today, Andrew Mok CFA from Barclays maintained a Buy rating on Elevance Health, with a price target of $404.00.

Claim 50% Off TipRanks Premium

According to TipRanks, Mok CFA is an analyst with an average return of -1.3% and a 53.16% success rate. Mok CFA covers the Healthcare sector, focusing on stocks such as Brookdale Senior Living, Acadia Healthcare, and CVS Health.

In addition to Barclays, Elevance Health also received a Buy from Truist Financial’s David S Macdonald in a report issued on January 27. However, yesterday, TipRanks – Anthropic downgraded Elevance Health (NYSE: ELV) to a Hold.

See the top stocks recommended by analysts >>

Based on Elevance Health’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $50.71 billion and a net profit of $1.19 billion. In comparison, last year the company earned a revenue of $45.15 billion and had a net profit of $1.02 billion

Read More on ELV:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).